Conclusion Despite increasing immune protection among young persons vaccinated after
birth, the estimated prevalence of persons living with chronic hepatitis B in the USA has …

Hepatocellular carcinoma (HCC) is the most common liver tumor, with a continually rising
incidence. The curative treatment for HCC is surgical resection or liver transplantation; …

Purpose In recent years, immune checkpoint inhibitors have been used in combination with
tyrosine kinase inhibitors and local therapies, creating a new era in treating hepatocellular …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death
globally. Currently there is a lack of tumor-selective and efficacious therapies for …

Tumor thrombus, the intravascular extension of tumor into adjacent blood vessels, is
frequently encountered in patients with renal cell carcinoma and hepatocellular carcinoma …

Background MRI is crucial in diagnosing hepatocellular carcinoma (HCC).
Superparamagnetic iron oxide particles (SPIO) are liver‐specific contrast agents which …

Background This phase I dose de-escalation study aimed to assess the tolerability, safety,
pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in …

原发性肝癌是常见的恶性肿瘤, 其中以肝细胞癌(hepatocellular carcinoma, HCC) 占大部分.
手术治疗是公认的能够使HCC 患者获得较好长期获益的方法, 但是大部分患者在诊断时已失去 …

Background The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide
and it is now the third most common cause of cancer-related death. HCC is becoming a …

Purpose The aim of this study was to clarify the adaptation of lenvatinib treatment in patients
with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Method Fifty …